Poging GOUD - Vrij
Results win customers. Leadership discipline keeps them
Express Pharma
|January 2026
Drawing themes from his new book The Dual Mandate in B2B - Driving Results. Shaping Culture, Mohan Joshi - Global C-Suite Partner & Former President, SCHOTT India, discusses leadership systems, alignment, and execution in conversation with Neha Aathavale.
-
What inspired you to write The Dual Mandate in B2B, and how is it different from your earlier book?
My inspiration came from a consistent observation across B2B ecosystems: organisations rarely struggle because of technical capability — they struggle because of inconsistent leadership actions. I saw high expertise but weak alignment, unclear assumptions, delayed communication and uneven ownership. These gaps silently weaken quality, documentation, supply reliability and customer confidence.
My first book, Real Time Growth with Customers, focused on the customer-facing side of the DIG 3×3 Framework. But the deeper challenge lies inside organisations — in how leaders think, communicate and act every day. That realisation shaped The Dual Mandate in B2B, which brings results and culture together through nine leadership drivers.
As I write in the book: “Results win customers. Leadership discipline keeps them.”
My perspective comes from working closely with global suppliers to pharma companies — the organisations responsible for quality, compliance, supply assurance and customer trust. This experience deepened my understanding of how pharma stakeholders operate and why alignment between partners strengthens long-term credibility.
The first book built the foundation through the customer lens. The Dual Mandate in B2B builds the leadership system behind it.
Where do organisations struggle more in B2B — driving performance or building culture?
Leaders often assume performance is the problem. In reality, challenges begin when leadership discipline becomes inconsistent.
You see this in patterns like:
● high activity but low clarity
● high communication but low alignment
● high reporting but low movement
These gaps reduce predictability, increase friction, and frustrate customers.
As I write: “Leaders rarely fail by moving slowly — they fail by moving blindly.”
Dit verhaal komt uit de January 2026-editie van Express Pharma.
Abonneer u op Magzter GOLD voor toegang tot duizenden zorgvuldig samengestelde premiumverhalen en meer dan 9000 tijdschriften en kranten.
Bent u al abonnee? Aanmelden
MEER VERHALEN VAN Express Pharma
Express Pharma
Speed and flexibility play a critical role in how we compete with larger global players
Kriti Jajoo, VP-BD and Strategy, Shriji Polymers, as the next-gen leader, speaks on how the company is evolving with a leadership approach that balances technology, sustainability, and customer-centricity to create long-term value, in an interview with Express Pharma
6 mins
January 2026
Express Pharma
Vizag rising: Shaping India's pharma future
At the Vizag Pharma Summit 2025, hosted by Express Pharma, industry leaders discussed how quality, R&D, compliance, and emerging technologies are driving India's next phase of pharma growth
9 mins
January 2026
Express Pharma
Future of pharma: Trends, challenges & AI
Industry experts discussed how Al is transforming pharmaceutical R&D, highlighting both the promise and the practical limitations of current technologies
2 mins
January 2026
Express Pharma
Gandhi Automations presents multi-composites, high-performance door PRIME NEO for clean environments
When it comes to pharmaceutical facilities and laboratories, clean rooms' hygiene and protection from environmental contamination are the most important factors to consider.
1 mins
January 2026
Express Pharma
Can Indian biosimilars and generics restate accessibility in global underserved markets?
Hari Kiran Chereddi, MD & CEO - HRV Pharma & NHG Pharma highlights that India's success in generics is no longer enough, as the world now demands advanced biologics, biosimilars, and personalised medicines. He further emphasises on the need for stronger regulation, innovation, and investment so India can lead in next-generation therapies and expand global access to cutting-edge healthcare
3 mins
January 2026
Express Pharma
The next wave of growth will belong not to the fastest manufacturers but to the most innovative problem-solvers
As India moves into 2026, industry experts state that the next phase of growth in pharmaceuticals will depend on strengthening formulation R&D, building a skilled and adaptable workforce, and closing gaps between academic research and industry needs.
6 mins
January 2026
Express Pharma
Results win customers. Leadership discipline keeps them
Drawing themes from his new book The Dual Mandate in B2B - Driving Results. Shaping Culture, Mohan Joshi - Global C-Suite Partner & Former President, SCHOTT India, discusses leadership systems, alignment, and execution in conversation with Neha Aathavale.
3 mins
January 2026
Express Pharma
INDIA'S INNOVATION JOURNEY FROM PROMISE TO PROOF
India's pharma ecosystem is ready to embrace stronger science and bolder ideas. Turning early breakthroughs into scalable, sustainable innovation remains the challenge
8 mins
January 2026
Express Pharma
PRUV® -The original Sodium Stearyl Fumarate
JRS Pharma's PRUV® is the original sodium stearyl fumarate (SSF) introduced in the market over 20 years ago
5 mins
January 2026
Express Pharma
Odisha's pharma pitch
The inaugural Odisha Pharma Summit 2025 delivered strong early signals of intent, positioning the state as an upcoming destination for PLI-triggered expansions, to complement existing pharma hubs. As Hemant Sharma, ACS Industry Dept and I&PR Dept, Govt of Odisha puts it, the aim is to “become a good, viable second option.” How fast can the eastern newcomer catch up and become India's next life sciences hub, asks Viveka Roychowdhury
5 mins
January 2026
Listen
Translate
Change font size
